Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis


First-in-human trial initiation in MS patients is imminent First-in-human trial initiation in MS patients is imminent

Continued here:
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis

Related Posts